Related Blog Posts from the Wikinvest Wire

Arena Pharmaceuticals (ARNA)   Subscribe to Arena Pharmaceuticals (ARNA) content from the Wikinvest Wire
 » Back to Arena Pharmaceu… (NASDAQ:ARNA) Stock Page

  

10/23/12(ARNA) Arena Pharmaceuticals Initiates PAH Study (Stock Blog Hub)

Arena Pharmaceuticals, Inc. (ARNA) recently initiated a phase I multiple dose study with APD811, which is being developed for the treatment of pulmonary arterial hypertension (PAH). Arena Pharma is expecting to enroll 30 healthy adult volunteers for this randomized, double-blind and placebo-controlled dose titration trial. The trial will study the safety, tolerability and pharmacokinetics of the [...]

4/19/12Arena Pharmaceuticals’ Outlook Hinges On Success Of Lorcaserin (Investment Underground » Page not found)

by Kelly Jamrozy The weight loss industry is a booming business, but one of the places it often struggles is with prescription weight loss drugs. This is at least partly because there have been so many weight loss drug disasters. Consumers are desperate for a quick-fix, but they realize danger often lurks behind the easiest solutions [...]

2/23/12U.S. Obesity Spells Opportunity for VVUS, OREX and ARNA (Phil’s Stock World)

Courtesy of Benzinga. Americans have gotten so irreversibly out of shape that the markets think we are going to need a [...]

5/26/11US Hot Stocks: MSFT, ARNA, CDTI, SYMS, EBS (Stock Wizard)

Microsoft Corporation (NASDAQ: MSFT) rallied more than 2% on Thursday after hedge-fund investor David Einhorn called for Microsoft Corp.’s board to replace Chief Executive Officer Steve Ballmer, saying the software maker suffers from “Charlie Brown management.” Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) jumped more than 12% after the company presented meta-analyses of the three trials in the lorcaserin Phase 3 clinical trial program at ECO 2011, the 18th European Congress on...

4/18/11Arena Pharmaceuticals Inc. (NASDAQ: ARNA) Q2 2011 Price Target (Value Investing Experiments)

Recent price: 1.29$P/E Ratio: -3 Months Target Price: 2$ Company DescriptionData provided by Reuters explains that Arena Pharmaceuticals Inc, incorporated on April 14, 1997, is a clinical-stage... Follow through to the website for more complete reports

4/4/11BioWatch: VIVUS & Orexigen Looking More FDA-Favorable (VVUS, OREX, ARNA) (Wall Street Sector Selector)

VIVUS Inc. (NASDAQ: VVUS) was recently shown as one of our five biotechs with 50% upside and news this morning is showing why VIVUS may be one of the only possible diet drugs which can get approval even with the FDA concerns.  Its shares are surging t...

1/27/11Arena Pharmaceuticals Receives FDA request For NDA Protocols (ARNA) (Hedge Accordingly)

Interesting development in biopharm/tech land... ARNA is down quite a bit after hours on release of some not so hot FDA news.. "Arena has receives a request from the FDA to submit protocols for the lorcaserin New Drug Application, prior to initiating certain studies, and expects to provide Arena with its comments and recommendations within approximately one month of each protocol submission. In December 2010, Arena reported on its discussions with the FDA at the end-of-review meeting...

1/6/11Performing Healthcare Sector’s Penny Stocks at NASDAQ: (ZLCS, OPXA, PPHM, ARNA, HNSN) (Penny Stock DD)

Zalicus, Inc. (NASDAQ:ZLCS) surged by 11.67% and closed at $2.01 with overall traded volume of 5.03 million shares in the last trading session. Its price to earnings ratio arrives at 6.93 times till its last trading session. The company is in highly profitability with ROE of 4.90%. Opexa Therapeutics Inc. (NASDAQ:OPXA) moved up by 53.85% [...]

1/2/11Performing Pharma Stocks at NASDAQ: (ARNA, WCRX, AVNR, SNSS, MELA) (Penny Stock DD)

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) gained by 0.58% and closed at $1.72 whereas overall traded volume stood at 3.41 million shares for the day. The current market price is 11.31% more than its last 50 days simple moving average. The company maintains strong short term liquidity position with current ratio of 4.76 times till it’s last [...]

12/20/10Most Active Stocks at NASDAQ Healthcare Sector: (ARNA, GILD, AMGN, MYL, HOLX) (Penny Stock DD)

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) surged by 7.14% and closed at $1.65 whereas overall traded volume stood at 13.73 million shares for the day. The value of 62.13 times depicts shows that the relative strength index is in overbought level. Its total market capitalization stood at $200.33 million. Gilead Sciences, Inc. (NASDAQ: GILD) witnessed the correction [...]

10/25/10(ARNA) Arena Pharmaceuticals is Denied FDA Approval for Obesity Candidate Drug (Stock Blog Hub)

The US Food and Drug Administration (FDA) dealt a major blow to Arena Pharmaceuticals (ARNA) by refusing to approve the company’s obesity candidate lorcaserin citing tumor-related safety concerns. The US regulatory authority issued a complete response letter (CRL) stating that the efficacy of the drug in non type II diabetes obese patients was found to [...]

10/25/10Hapoalim Securities Doesn't See Strong Future For Arena Pharmaceuticals (ARNA) (Benzinga)

Hapoalim Securities doesn't see a light at the end of the tunnel for Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) in the near future. It lowered its price target to $1.50 from $2 and is reiterating its Sell rating. In a note to clients, Hapoalim writes, "Arena intends to request a Type A meeting with the FDA to clarify its requests, and, if the meeting is granted, the FDA's guidance states that it should occur within 30 days of the request. Because the path forward for lorcaserin will need...

10/25/10FDA Issues Complete Response For Arena's Lorcaserin (Benzinga)

On 10/23, Arena Pharmaceuticals (NASDAQ: ARNA) announced the FDA issued a complete response letter (CRL) for lorcaserin, citing several reasons for delaying the drug's approval. The CRL focused on lorcaserin's potential cancer risk and modest clinical efficacy, requesting additional preclinical data and ph.III BLOOM-DM results, minimally. Oppenheimer believes there is meaningful risk the FDA will eventually request additional clinical trials in order to address concer ns regarding...

10/20/10Arena Pharmaceuticals Announces Phase 1 Results for APD916 (Benzinga)

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today results from a Phase 1 clinical trial of APD916, a novel drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy with cataplexy. The randomized, double-blind and placebo-controlled trial evaluated the safety, tolerability and pharmacokinetics of 1 mg, 3 mg and 5 mg single doses of APD916. The trial evaluated 24 healthy volunteers in three cohorts of eight participants each, six...

10/4/10Requested Chart Analysis for Arena Pharmaceuticals (ARNA): Bullish Engulfing Pattern ()

Below is a highly requested chart analysis from Monday’s action. Arena Pharmaceuticals (ARNA) [caption id="attachment_1744" align="aligncenter" width="150" caption="Click with Hand to Enlarge"][/caption] A/D line: A strong negative trend which signaled a potential start of a reversal today ADX line:  bearish trend MACD: Nearing a buy signal CMF (21): Bearish, anything -.50 or lower is very bearish. OBV: Confirmed all moves in the [...]

10/4/10Readers Pick Drug Approval Winners & Losers (Benzinga)

BOSTON (TheStreet) -- The opioid addiction drug from Alkermes (Nasdaq: ALKS) is a lock for U.S. approval later this month, as are a new diabetes drug from Amylin Pharmaceuticals (Nasdaq: AMLN) and partners and an antibiotic made by Forest Labs (NYSE: FRX). The respective weight-loss drugs from Arena Pharmaceuticals (Nasdaq: ARNA) and Vivus (Nasdaq: VVUS), however, stand almost no chance of receiving the backing of U.S. drug regulators. Those are some of the consensus opinions that stand...

9/17/10Zings Of The Day (ARNA, GS, ORCL, RIMM) (Benzinga)

Arena Pharmaceuticals (NASDAQ: ARNA) failed to convince the FDA that its obesity drug was safe. One of the major concerns was the dead mice in the trials. The company didn't disclose this because it didn't feel it was material. Who let company management in? Jojo the idiot circus boy? Research In Motion (NASDAQ: RIMM) reported better than expected earnings yesterday, despite shipping fewer devices than analysts had predicted. The company blamed this on lagging sales of the Blackberry...

9/17/10Arena Pharma Craters on FDA Rejection (ARNA) (Benzinga)

Shares of Arena Pharmaceuticals (NASDAQ: ARNA) are lower on the session by 45.19%, currently trading at $2.05. The stock is falling today after the U.S. Food and Drug Administration voting against the approval of ARNA's obesity drug, Lorcaserin. The FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 9 to 5 that the available data do not adequately demonstrate that the potential benefits of Lorcaserin outweigh the potential risks, when used long-term in a population of...

9/17/10Arena Downgraded To Neutral (Benzinga)

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) had the FDA AdComm panel for Lorcaserin vote 5-9 against approval, owed largely to carcinogenicity concerns in light of the modest weight loss benefit, approval now pushed for at least three years, maybe even to 2015, Piper Jaffray reports. Piper Jaffray has downgraded Arena to Neutral, and the discount rate has been increased to 40% (from 20%). Price target has also been lowered to $1.50 (from $10). Arena Pharmaceuticals, Inc. closed yesterday...

9/17/10Benzinga's Top Pre-Market NASDAQ Losers (ARNA, OREX, ACFN, VVUS) (Benzinga)

Arena Pharmaceuticals Inc (NASDAQ: ARNA) dipped 44.12% to $2.09 in the pre-market session. Analysts at Piper Jaffray downgrade ARNA from "overweight" to "neutral." Orexigen Therapeutics Inc (NASDAQ: OREX) lost 9.01% to $6.16 in the pre-market session. OREX shares have fallen 26.65% over the past 52-weeks, while the S&P500 index has gained 5.55% in the same period. Acorn Energy Inc (NASDAQ: ACFN) fell 6.58% to $4.40 in the pre-market session. ACFN shares have fallen 15.44% over the past...

9/17/10Day Trader's Alert: CRXL, ARNA, ALKS (Stock Wizard)

Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NASDAQ: CRXL) today announced that they are in advanced negotiations for a potential public offer by Johnson & Johnson or an affiliate for all outstanding ordinary shares of Crucell not already held by Johnson & Johnson and its affiliates. Johnson & Johnson, through an affiliate, currently holds approximately 17.9 percent of the outstanding shares of Crucell and has submitted a statement on Schedule 13D to the U.S. Securities and Exchange...

9/17/10Hapoalim Securities Reiterates Sell On Arena Pharmaceuticals (ARNA) (Benzinga)

Hapoalim Securities is out this morning with a research report reiterating its Sell rating on Arena Pharmaceuticals (NASDAQ: ARNA) after the company did not impress the FDA with its weight loss drug, Lorcaserin. It has a $2 price target on shares. In the research note, Hapoalim writes, "As expected based on the reviewing documents, an expert panel voted 9 against and 5 for the approval of lorcaserin for obesity. The primary concerns were related to the potential safety issues, especially...

9/17/10Benzinga's Top Downgrades (IGT, MEE, ARNA, NBL) (Benzinga)

Janney Montgomery downgraded International Game Technology (NYSE: IGT) from "buy" to "neutral." IGT's shares closed at $15.10 yesterday. International Game Technology's earnings are likely to fall by 54.15% this year. Macquarie downgraded Massey Energy Company (NYSE: MEE) from "outperform" to "neutral." MEE's stock closed at $32.36 yesterday. Massey Energy's quarterly earnings dipped 471.37% y/y. Arena Pharmaceuticals Inc (NASDAQ: ARNA) was downgraded by Davenport from “buy” to...

9/16/10Arena Pharmaceuticals Falls 40% On FDA Rejection (ARNA) (Benzinga)

A federal advisory panel has rejected Arena Pharmaceuticals (NASDAQ: ARNA) weight loss drug lorcaserin on concerns the drug didn't work well and also carried potential safety problems. The advisory panel voted 5 to 9 against the drug. Essentially, the panel's vote amounts to a recommendation that the FDA not approve the drug. Although the FDA is not required to follow the panel's advice, it usually does. In a statement, Jack Lief, Arena's chief executive said, "Arena and Eisai believe that...

9/16/10Arena and Eisai Provide Update on Lorcaserin FDA Meeting (Benzinga)

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 9 to 5 that the available data do not adequately demonstrate that the potential benefits of lorcaserin outweigh the potential risks, when used long-term in a population of overweight and obese individuals to allow marketing approval. Lorcaserin, which Arena discovered and has developed, is intended for weight...

9/16/10Strong Response To Live Blog On Arena (ARNA) (Benzinga)

TheStreet.com's senior biotech columnist Adam Feuerstein had a live blog today, in which he discussed the Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) ruling from the FDA on its weight loss drug, lorcaserin. The blog had more 5,000 readers, and almost 350,000 page views, an unprecedented number of page views. This is a tremendous amount of traffic, and goes to show that the web and new forms of social media are here to stay for financial news. Congratulations Adam on the success of the...

9/15/10Wednesday's Mid-Day Options Volume Leaders (YHOO, ARNA, AAPL, BAC, C) (Benzinga)

The overall market is struggling with the flat-line today; currently, the S&P 500 (CBOE: SPX) is lower by 1.86 points, trading at $1,119. This is actually bullish and constructive considering the strong rally we have just seen and the fact that we are at the high end of the range. Here are your mid-day options volume leaders… 1. Yahoo Inc. (NASDAQ: YHOO) 117,330 contracts, 78.9% calls, 21.1% puts 2. Arena Pharma (NASDAQ: ARNA) 91,762 contracts, 74.3% calls, 25.7% puts 3. Apple Inc....

9/15/10Benzinga's Top Pre-Market NASDAQ Losers (ARNA, ATML, RDWR, LOGI) (Benzinga)

Arena Pharmaceuticals Inc (NASDAQ: ARNA) dipped 6.05% to $3.88 in the pre-market session. The FDA's decision on ARNA's new weight loss drug, Lorcaserin, is due on September 16. Atmel Corporation (NASDAQ: ATML) lost 4.78% to $6.58 in the pre-market session. ATML had launched the Atmel QTouch Studio 4.3, industry's first software tool that supports the overall touch design flow. Radware Ltd (NASDAQ: RDWR) fell 4.33% to $36.92 in the pre-market session. RDWR's shares have jumped 224.01% over...

9/15/10Hapoalim Securities Lowering Price Target On Arena Pharmaceuticals (ARNA) (Benzinga)

Hapoalim Securities is lowering its price target on Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) to $2 and reiterating its Sell rating, after the initial FDA findings were released yesterday on its lorcaserin drug. In the research note, Hapoalim Securities writes, "Yesterday, the FDA posted its review of lorcaserin, questioning both efficacy and safety. The fact that malignancies of multiple types were seen in rats treated with high doses was quite surprising to us and an FDA reviewer...

9/14/10Arena Tumbles Ahead of FDA Review (ARNA, VVUS, OREX) (tickerspy.com)

Arena Pharmaceuticals (ARNA) shares slid by -30% on Tuesday after the U.S. Food and Drug Administration staff said that one of the company's lorcaserin diet drug doses met one set of agency criteria for effectiveness "by a slim margin." According to coverage by ABC News, Arena studies showed that patients taking 10 milligrams of [...]

9/14/10Correction: Arena Hit Hard After Initial FDA Findings (ARNA) (Benzinga)

A previous Benzinga article reported erroneously that the FDA had already ruled on the Arena Pharmaceuticals (NASDAQ: ARNA) drug for weight loss. The ruling is not until Thursday. The initial findings were released, in which the FDA said there were three noteworthy safety issues" found in the testing of rats. Shares are down sharply on this news. Benzinga regrets this error. You Can't Afford Miss To Out On These Money Making Trading Ideas.

9/14/10Arena Pharma Down 40% on FDA Leak (ARNA) (Benzinga)

Shares of Arena Pharmaceuticals Inc. (NASDAQ: ARNA) are lower by 39.85%, currently trading at $4.12. The stock is cratering today on a leak of FDA news that Arena's weight loss drug, Lorcaserin, is effective only “by a slim margin.” The U.S. Food and Drug Administration is set to release its findings on Lorcaserin this Thursday. ARNA will then hold a webcast to discuss the ruling Friday morning, at 7:00 am est. Options trading is mixed in the name, so far. As of 9:50 est, 40,000...

9/14/10Benzinga's Top Pre-Market NASDAQ Losers (ARMH, NUVA, ARNA, THQI) (Benzinga)

ARM Holdings Plc (NASDAQ: ARMH) dipped 5.33% to $17.77 in the pre-market session. ARMH's shares have gained 176.03% over the past 52 weeks, while the S&P500 index has just gained 6.91% in the same period. NuVasive Inc (NASDAQ: NUVA) lost 4.94% to $30.00 in the pre-market session. NUVA has narrowed its 2010 revenue guidance range from $485 million - $500 million to $485 - $495 million. Arena Pharmaceuticals Inc (NASDAQ: ARNA) fell 3.94% to $6.58 in the pre-market session. Analysts at...

9/13/10Benzinga's Top Pre-Market NASDAQ Losers (SGEN, ARNA, HGSI, GOLD) (Benzinga)

Seattle Genetics Inc (NASDAQ: SGEN) dipped 4.87% to $12.10 in the pre-market session. SGEN's leukemia drug, Lintuzumab for acute meyeloid leukemia (AML) patients, has failed its trial. Arena Pharmaceuticals Inc (NASDAQ: ARNA) lost 0.71% to $6.96 in the pre-market session. ARNA's trailing-twelve-month operating margin tumbled 1,051.95%. Human Genome Sciences Inc (NASDAQ: HGSI) fell 0.47% to $29.85 in the pre-market session. HGSI's trailing-twelve-month operating margin fell...

7/19/10Results of my Newsletter Picks last night (Penny Stock DD)

VocalTec Communications Ltd. (NASDAQ: VOCL) - Shares are down 4.85% and hitting an intraday low of $14.50 after VOCL completed a reverse merger, which tends to move stock prices lower. Will shares bounce back to $16.50? Stay tune. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) jumped 12.88% to $5.26 on 13.96 [...]

7/1/10Some of Bigger Winners Wednesday (Penny Stock DD)

Among the biggest winners in Thursday's early trading are Arena Pharma (Nasdaq: ARNA), Christopher & Banks (NYSE: CBK) and BJ’s Wholesale (NYSE: BJS). Top Percentage Gainers -- Thursday, July 1, 2010 Company Name (Ticker) Intra-Day Price Intra-Day % Gain 52-Week High 52-Week Low Christopher & Banks (NYSE: CBK) $7.21 +16.5% $11.60 $5.37 BJ's Wholesale (NYSE: BJ) $42.01 +13.5% $29.73 $43.83 Arena Pharma (Nasdaq:...

6/23/10A solid DRD Pick ARNA: NASDAQ a Biopharma stock (Penny Stock DD)

Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. The Company’s advanced drug candidate is lorcaserin hydrochloride (lorcaserin), for weight management, which has [...]

12/28/09(MRK) Merck & Co Ends Deal with Arena Pharmaceuticals (Stock Blog Hub)

Merck & Co (MRK) recently informed its partner Arena Pharmaceuticals (ARNA) that it was pulling out of a collaboration agreement pertaining to the development of an atherosclerosis drug. The decision by Merck to discontinue the development of the candidate, MK-1903, a niacin receptor agonist for treating atherosclerosis, followed disappointing results from a recently completed mid-stage study. [...]

11/2/09(ARNA) Amylin Pharmaceuticals Strikes First on Obesity (Stock Blog Hub)

Almost all of the news in the obesity race has been made recently by three small biotech companies -- Arena Pharmaceuticals (ARNA), Vivus Inc. (VVUS) and Orexigen Therapeutics (OREX), but yesterday it was mid-cap Amylin Pharmaceuticals (AMLN) that signed the first partnership in what was originally perceived to be a three-horse race. Amylin and Takeda Pharmaceutical [...]

10/26/09Intraday action (AlphaNinja)

After a very strong open, the DJIA has dropped 140 points to current lows, down nearly half a percent. JPMorgan(JPM) and Bank of America(BAC) are the worst Dow performers, possibly due to comments from the FDIC suggesting that banks need to be more aggressive about writing down the value of commercial real estate loans. Among gainers today are Vivus (VVUS) and Arena Pharma (ARNA), up on excitement about their obesity drugs. Other biotech names are up due to swine-flu fears. Leading...

9/21/09(ARNA) Arena Pharmaceuticals’ Lorcaserin Has Safety Edge (Stock Blog Hub)

Results from Arena Pharmaceuticals’ (ARNA) phase III BLOSSOM study are strikingly similar to the BLOOM study, with mean total weight loss for the 10mg lorcaserin BID group coming in at 17.0 lbs in BLOSSOM vs. 17.9 lbs in BLOOM. These equated to 7.9% and 8.2% mean absolute weight loss. The placebo was 3.9% and 3.4% in each [...]

9/18/09BioMed News Bytes: Arena (NASDAQ: ARNA), Momenta (NASDAQ:MNTA), Vivus (NASDAQ: VVUS) ()

On 9/18/09, Arena Pharma (NASDAQ: ARNA ) ($5.32, +9%) (heavy, above-average volume) announced lorcaserin met all primary endpoints and FDA benchmark with 63% of patients who complied with the protocol losing at least 5% of their weight. ARNA plans to file a NDA with the FDA in December. However, patients who took lorcaserin 10 mg twice daily achieved an average weight loss of 5.9% of their body weight, compared to 2.8% for placebo, causing shares of ARNA to initially decline on the news...

9/17/09BioMed News Bytes: Arena (NASDAQ: ARNA), ImmunoCellular (OTC: IMUC.OB), YM Bio (AMEX: YMI) ()

Shares of Arena Pharma (NASDAQ: ARNA ) (AH $6.58, +34% at 5:10pm ET on heavy, above-average volume for the day) are surging on news that the Company will conduct a conference call Friday 18-September at 8am ET to discuss the BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 study (its second pivotal Phase 3 study for this compound) results for its experimental weight loss drug lorcaserin and expects to submit a NDA for FDA approval by year-end based...

12/9/08The VIX Declines, Arena Pharmaceuticals (ARNA) Surges (Contrarian Profits)

This may turn out to be the week options traders have been waiting for. Since this economic crisis began to unfold in early September, the CBOE’s volatility index (the VIX) has soared to record levels. Only recently has the upward pressure begun to wane. Today, the situation for the VIX is looking quite intriguing. The highly [...]

3/26/08Lorcaserin's safety data should result in a good partnership deal for Arena Pharmaceuticals (Biotechnology Stock)

On March 17 th , Arena Pharmaceuticals ( ARNA ) reported that they will continue with phase III trials after an independent review of unblinded data showed no cardiac safety concerns for the weight loss drug, Lorcaserin. This was a rather important result for Arena because there had been concerns that it may have similar heart valve problems that plagued fen- phen, which targeted the same receptor. I have written in the past about the differences in the selectivity in these drugs which...

1/20/08January 2008 Performance Review (Biotechnology Stock)

It is time again to review past picks and to learn about my mistakes. The table below includes a list of my historical picks. ARNA and ALTU stand out as worst performing picks. Interestingly they are both small cap picks, so this drop is not so unexpected. I am removing ALTU from my picks due to current conflicts of interest. ARNA ( link to original post) has suffered because they have not announced a partner yet for its weight loss drug Lorcaserin . This is probably because...

10/21/06Phase II results suggest Lorcaserin is an effective and safe weight loss treatment - Arena Pharma... (Biotechnology Stock)

Arena Pharmaceuticals, Inc ( San Diego, California ) is a biopharmaceutical with five clinical stage candidates addressing four large disease indications including: obesity, cardiovascular diseases, insomnia and diabetes. Arena utilizes a proprietary technology platform, called Constitutively Activated Receptor Technology (CART) and Melanophore, to develop orally available small molecule candidates directed at modulating G protein-coupled receptors (GPCRs). GPCRs are a class of receptors...


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki